Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.
New results from its Phase II safety trial show the LDL-cholesterol lowerer was not associated with a major increase in adverse events vs. standard of care.
An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.
The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.
The drug maker is adding Amplimunne's cancer portfolio to subsidiary MedImmune's oncology efforts, one of several recent deals to add heft.
Analyst Seamus Fernandez writes that Merck needs to undergo a deep overhaul, continuing the summer narrative that has enveloped Pfizer and Novartis.
Phase III results of Eli Lilly lung cancer drug necitumumab took analysts by surprise on two levels: by helping it avoid the dustbin and in succeeding where Erbitux had failed.
The Indiana drug maker logged a 6% sales increase over the same period last year. Higher prices were responsible for the majority of the growth.
A Data and Safety Monitoring Board recommendation has wiped aleglitazar from the drug maker's slate of possible diabetes medications.
The regulator says Merck needs to focus on lower doses of the drug.
ASCO not only offered a peek at developing treatments likely to be commercialized. Its impact also put some companies in the limelight from a business-development perspective.
Eli Lilly's GLP-1 drug is still in Phase III, but recently released data suggest it could be a formidable competitor to the already marketed GLP-1 drugs, including Novo's market-leading Victoza.
The pharmaceutical behemoth is betting at least $650 million on the Aragon Pharmaceuticals Ph. II drug.
Novartis is advancing its "breakthrough" lung cancer drug into Phase III based on promising Phase I data.
GSK's newest cancer approvals highlight a problem that stalks progress with personalized medicines.
Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement.
J&J scored an unexpected "priority review status" for its HCV agent simeprivir, whose initial approval is expected to be with interferon.
Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective.
FDA is accelerating review of Pfizer's experimental breast cancer drug palbociclib, which analysts say already has a fan base among KOLs.
Roche's oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive.
Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016.
HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.
Boehringer, Horizon Discovery sign collaboration agreement; GSK files for HGS diabetes therapy
Transparency Life Sciences is tapping the wisdom of the crowd, with FDA's imprimatur, in an effort to make the drug development process more sustainable.
Researchers said the industry closed 2012 with a mixed bag of results. The upside: more approvals than last year. The downside: projected sales for these new drugs is less.
The drug maker will roll out another Phase III trial.
Gilead's $510 million deal to buy YM Biosciences will bring an experimental bone marrow therapy under its roof.
Janssen's prostate cancer pill Zytgia got an OK for use in an earlier line of therapy, and drugmakers Pfizer, Bristol-Myers Squibb and Boehringer Ingelheim released new data on blood thinners Eliquis and Pradaxa.
Takeda is plunking down $140 million for Envoy Therapeutics and its CNS tech
Eli Lilly said its Phase III AWARD trials for its weekly dulaglutide GLP-1 drug, in testing for type 2 diabetes, met primary efficacy endpoints and demonstrated superiority for HbA1c lowering over exenatide and metformin.